No longer relegated to being studied in murine models...
https://ard.bmj.com/content/78/Suppl_2/1692.2
Seletalisib is a potent, selective oral inhibitor of phosphoinositide-3 kinase delta (PI3Kδ). Preclinical data have shown that the PI3Kδ pathway is upregulated within salivary glands of patients with PSS and contributes to disease pathogenesis.
https://clinicaltrials.gov/ct2/show/NCT02610543
https://sjogrenssyndromenews.com/2019/01/15/seletalisib-improves-saliva-flow-lowers-inflammation/
It will be interesting to see what happens in lager Phase-III trials...